No Data
No Data
HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
H.C. Wainwright analyst Emily Bodnar maintains $Purple Biotech(PPBT.US)$ with a buy rating, and adjusts the target price from $200 to $33.According to TipRanks data, the analyst has a success rate
Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival
Purple Biotech Reveals Optimistic Cancer Treatment Data
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Purple Biotech To Carry Out 1-for-20 Reverse Stock Split On September 17th, 2024
September 12th (Eastern Time) - $Purple Biotech(PPBT.US)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from September 17th,